Clinical Trial Update: To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating esomeprazole 20 mg once daily in patients with gastroesophageal reflux disease who continued heartburn after rabeprazole treatment; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease
• Reflux Esophagitis

Drugs mentioned

• Esomeprazole (Esomeprazole)
• Rabeprazole (rabeprazole)

Snippet

Sponsor: AstraZeneca | Conditions: Gastroesophageal Reflux Disease, GERD | Phase 4 | Status: COMPLETED | Results posted: 2013-02-18